These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24141140)

  • 1. Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis.
    Caretti A; Bragonzi A; Facchini M; De Fino I; Riva C; Gasco P; Musicanti C; Casas J; Fabriàs G; Ghidoni R; Signorelli P
    Biochim Biophys Acta; 2014 Jan; 1840(1):586-94. PubMed ID: 24141140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ceramide de novo synthesis by myriocin produces the double effect of reducing pathological inflammation and exerting antifungal activity against A. fumigatus airways infection.
    Caretti A; Torelli R; Perdoni F; Falleni M; Tosi D; Zulueta A; Casas J; Sanguinetti M; Ghidoni R; Borghi E; Signorelli P
    Biochim Biophys Acta; 2016 Jun; 1860(6):1089-97. PubMed ID: 26922830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids.
    Caretti A; Vasso M; Bonezzi FT; Gallina A; Trinchera M; Rossi A; Adami R; Casas J; Falleni M; Tosi D; Bragonzi A; Ghidoni R; Gelfi C; Signorelli P
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Aug; 390(8):775-790. PubMed ID: 28439630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.
    Becker KA; Riethmüller J; Lüth A; Döring G; Kleuser B; Gulbins E
    Am J Respir Cell Mol Biol; 2010 Jun; 42(6):716-24. PubMed ID: 19635928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis.
    Mingione A; Dei Cas M; Bonezzi F; Caretti A; Piccoli M; Anastasia L; Ghidoni R; Paroni R; Signorelli P
    Cell Physiol Biochem; 2020 Jan; 54(1):110-125. PubMed ID: 31999897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myriocin modulates the altered lipid metabolism and storage in cystic fibrosis.
    Signorelli P; Pivari F; Barcella M; Merelli I; Zulueta A; Dei Cas M; Rosso L; Ghidoni R; Caretti A; Paroni R; Mingione A
    Cell Signal; 2021 May; 81():109928. PubMed ID: 33482299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulators of sphingolipid metabolism reduce lung inflammation.
    Dechecchi MC; Nicolis E; Mazzi P; Cioffi F; Bezzerri V; Lampronti I; Huang S; Wiszniewski L; Gambari R; Scupoli MT; Berton G; Cabrini G
    Am J Respir Cell Mol Biol; 2011 Oct; 45(4):825-33. PubMed ID: 21659660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic Fibrosis Defective Response to Infection Involves Autophagy and Lipid Metabolism.
    Mingione A; Ottaviano E; Barcella M; Merelli I; Rosso L; Armeni T; Cirilli N; Ghidoni R; Borghi E; Signorelli P
    Cells; 2020 Aug; 9(8):. PubMed ID: 32781626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.
    Guilbault C; De Sanctis JB; Wojewodka G; Saeed Z; Lachance C; Skinner TA; Vilela RM; Kubow S; Lands LC; Hajduch M; Matouk E; Radzioch D
    Am J Respir Cell Mol Biol; 2008 Jan; 38(1):47-56. PubMed ID: 17656682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis.
    Gardner AI; Haq IJ; Simpson AJ; Becker KA; Gallagher J; Saint-Criq V; Verdon B; Mavin E; Trigg A; Gray MA; Koulman A; McDonnell MJ; Fisher AJ; Kramer EL; Clancy JP; Ward C; Schuchman EH; Gulbins E; Brodlie M
    Am J Respir Crit Care Med; 2020 Oct; 202(8):1133-1145. PubMed ID: 32569477
    [No Abstract]   [Full Text] [Related]  

  • 11. TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells.
    John G; Yildirim AO; Rubin BK; Gruenert DC; Henke MO
    Am J Respir Cell Mol Biol; 2010 Apr; 42(4):424-31. PubMed ID: 19502387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by
    Marteyn BS; Burgel PR; Meijer L; Witko-Sarsat V
    Front Cell Infect Microbiol; 2017; 7():243. PubMed ID: 28713772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of ceramide de novo synthesis in solid tissues changes sphingolipid levels in rat plasma, erythrocytes and platelets.
    Błachnio-Zabielska A; Baranowski M; Wójcik B; Górski J
    Adv Med Sci; 2016 Mar; 61(1):72-7. PubMed ID: 26521206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.
    Stotland PK; Radzioch D; Stevenson MM
    Pediatr Pulmonol; 2000 Nov; 30(5):413-24. PubMed ID: 11064433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of de novo ceramide synthesis in pro-inflammatory adipokine secretion and adipocyte-macrophage interaction.
    Hamada Y; Nagasaki H; Fujiya A; Seino Y; Shang QL; Suzuki T; Hashimoto H; Oiso Y
    J Nutr Biochem; 2014 Dec; 25(12):1309-16. PubMed ID: 25283329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbial interaction: Prevotella spp. reduce P. aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells.
    Bertelsen A; Elborn JS; Schock BC
    J Cyst Fibros; 2021 Jul; 20(4):682-691. PubMed ID: 34112603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.
    Karandashova S; Kummarapurugu A; Zheng S; Kang L; Sun S; Rubin BK; Voynow JA
    Pediatr Pulmonol; 2018 Jul; 53(7):872-880. PubMed ID: 29624923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of ceramide de novo biosynthesis rescue damages induced by cigarette smoke in airways epithelia.
    Zulueta A; Caretti A; Campisi GM; Brizzolari A; Abad JL; Paroni R; Signorelli P; Ghidoni R
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jul; 390(7):753-759. PubMed ID: 28409208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.
    Hsu D; Taylor P; Fletcher D; van Heeckeren R; Eastman J; van Heeckeren A; Davis P; Chmiel JF; Pearlman E; Bonfield TL
    Infect Immun; 2016 Sep; 84(9):2410-21. PubMed ID: 27271746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.